Prof R. Khanna

Rajiv Khanna

Queensland Institute of Medical Research, QLD

Prof. Rajiv Khanna obtained his doctorate degree from India and undertook his post-doctoral training at the University of Adelaide and the Queensland Institute of Medical Research (QIMR), Brisbane Australia. He is currently appointed as the Director of the Centre for Immunotherapy and Vaccine Development at QIMR and also holds Senior Principal Research Fellowship from the National Health and Medical Research Council of Australia. The major goals of his research group are to obtain a deeper understanding of the mechanisms by which an immune response to human herpesviruses associated diseases may be generated, augmented and applied to control these diseases. Over the last few years, Prof. Khanna has successfully translated his research towards the development of novel immune-based therapeutic strategies for the treatment of patients with herpesvirus-associated complications and is currently lead investigator on five clinical trials. He has published more than 150 scientific papers in leading journals and holds numerous international patents on EBV and human cytomegalovirus (CMV)  and has successfully co-developed a diagnostic kit (QuantiFERON-CMV) in collaboration with Cellestis Ltd (now QIAGEN).  QuantiFERON-CMV has been CE marked in Europe for diagnostic application and is expected to be launched in US in late 2013. Currently, he is also collaborating with Intercell AG (now Valneva SE) to develop a new prophylactic vaccine against CMV.